Índice de risco de malignidade para tumores do ovário incorporando idade, ultra-sonografia e o CA-125

Fernandes, Luís Roberto Araujo; Lippi, Umberto Gazi; Baracat, Fausto Farah

doi:10.1590/s0100-72032003000500007

Cited by 7 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is rare the appearance of epithelial ovarian cancer before age 30. The age group with the highest incidence is over 50 years [79].…”

Section: Ovarian Cancermentioning

confidence: 99%

The Risk of Relationship between Hormonal Replacement Therapy and Cancer

Rosales¹

2014

CRJ

View full text Add to dashboard Cite

Abstract:Menopause is an endocrine condition due to the decline in ovarian activity, which occurs in all women and is characterized as a progressive hypoestrogenism. To minimize damage from lack hormonal activity, hormone replacement therapy has been developed (TRH), which is widely used around the world, often without criteria pre-established. Thus, this study aims to identify hormonal therapies used postmenopausal and relate them to the development of tumors. In addition, identify the criteria for the use of HRT, the utilization time and women who are part of the risk groups are also objectives of this study. In the beginning, the clinical methodology of HRT included only estrogen, but epidemiological studies have observed that the progestin presence is essential in endometrial hyperplasia control adding to the therapy. Progestogens act depending on its molecular structure, and consequently selectivity, or may interact with other steroid receptors. From this interaction, different pharmacodynamic answers about importance in the development of tumors can be observed, ie, progesterone activity, estrogen, antiestrogen, androgen and / or antiandrogen. In view of the mechanism of carcinogen administration of estrogens, it can be said that HRT increases the risk of breast, uterus and ovary cancer. However, the estrogenic actions may be adjusted when there is administration of progestin drugs and with antiestrogenic and antiandrogenic actions. Given this, in menopausal women, it is advisable to trace gynecological cancer, before, during and after any therapeutic interventions, and the decision of using and the choice of HRT on an individual basis, through a careful assessment of signs and symptoms and long-term risk.

show abstract

“…It is rare the appearance of epithelial ovarian cancer before age 30. The age group with the highest incidence is over 50 years [79].…”

Section: Ovarian Cancermentioning

confidence: 99%

The Risk of Relationship between Hormonal Replacement Therapy and Cancer

Rosales¹

2014

CRJ

View full text Add to dashboard Cite

show abstract

“…Conceptually, all benign neoplasms are classified as well-differentiated tumors due to their biological behavior. The most frequent ovarian neoplasms include serous and/or mucinous cystadenoma, serous or mucinous cystadenocarcinoma, granulosa cell tumors, fibromas/thecomas and teratomas (mature or immature) (1,10,11,21) .…”

Section: Introductionmentioning

confidence: 99%

The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasms

Cambruzzi¹,

Lima²,

Teixeira³

et al. 2014

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Introduction: Primary ovarian neoplasms exhibit a wide range of histopathological aspects, and tumors with epithelial differentiation are the most frequent. Among the malignant tumors, the most common histological type corresponds to serous adenocarcinoma, whose diagnosis is established in advanced stages of the disease in approximately 75% of the patients. Tumor marker CA 125 represents a glycoprotein synthesized mainly by neoplastic cells with epithelial differentiation, and its serum level seems to be associated with the biological potential of these lesions. Objective: To estimate the association between serum levels of CA 125 and the degree of differentiation in primary ovarian neoplasms.

show abstract

“…Ultrasonography is an important tool in the evaluation of adnexal masses and in the definition of differential diagnosis for such conditions (1) . In children, because of the limitations of clinical examination, abdominal ultrasonography becomes a pref-agnosis between malignant and benign adnexal masses, although several authors have reported similar results demonstrating a high diagnostic accuracy of the method (3)(4)(5)(6)(7)(8)(9) . The operator must be familiar with all possible presentations of a normal ovary as well as with the characteristics of probably benign or malignant lesions.…”

Section: Introductionmentioning

confidence: 99%

“…The operator must be familiar with all possible presentations of a normal ovary as well as with the characteristics of probably benign or malignant lesions. Tridimensional ultrasonography and Doppler as well as tumor markers, namely, CA-125, CA-15.3, CA-19.9, CA-72.4 and alpha-fetoprotein blood tests are recommended as adjuvant methods in the differential diagnosis of adnexal masses, considering that they increase the sensitivity and specificity in the differentiation of ovarian tumors (9)(10)(11)(12) .…”

Section: Introductionmentioning

confidence: 99%